Studies related to Symptoms of OCD and N-Acetylcysteine

N-acetylcysteine Add-on Treatment In Refractory Obsessive-compulsive Disorder: A Randomized, Double-blind, Placebo-controlled Trial

Effect Decrease
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 48
Sex Both Genders
Age Range 18-29, 30-44
Body Types Average
Notes for this study:
12 weeks supplementation of N-acetylcysteine up to 2,400mg daily in persons with OCD who were being mediated (with SRIs) but were unresponsive to said mediciation noted that the response rate in reducing symptoms of OCD rose from 15% in placebo to 52.6% in the NAC group (a 'response' being a 35% reduction in symptoms or more); this is thought to be due to NAC being able to reverse or attenuate resistance to SRI therapy.